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Abstract
Conventional differential expression analyses have been successfully employed to identify
genes whose levels change across experimental conditions. One limitation of this approach
is the inability to discover central regulators that control gene expression networks. In addi-
tion, while methods for identifying central nodes in a network are widely implemented, the
bioinformatics validation process and the theoretical error estimates that reflect the uncer-
tainty in each step of the analysis are rarely considered. Using the betweenness centrality
measure, we identified Etv5 as a potential tissue-level regulator in murine neurofibromatosis
type 1 (Nf1) low-grade brain tumors (optic gliomas). As such, the expression of Etv5 and
Etv5 target genes were increased in multiple independently-generated mouse optic glioma
models relative to non-neoplastic (normal healthy) optic nerves, as well as in the cognate
human tumors (pilocytic astrocytoma) relative to normal human brain. Importantly, differen-
tial Etv5 and Etv5 network expression was not directly the result of Nf1 gene dysfunction in
specific cell types, but rather reflects a property of the tumor as an aggregate tissue. More-
over, this differential Etv5 expression was independently validated at the RNA and protein
levels. Taken together, the combined use of network analysis, differential RNA expression
findings, and experimental validation highlights the potential of the computational network
approach to provide new insights into tumor biology.
Introduction
Similar to other ecological systems, mammalian tissues can also be considered as complex bio-
logical systems, composed of a multitude of cellular and acellular elements that each contribute
to overall biosystem function. In this regard, both normal and disease tissues contain numer-
ous distinct cell types and molecular components that bi-directionally interact to establish new
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Data Availability Statement: Details of Datasets
RNA-Seq Data for 3-month-old murine non-
neoplastic and OPG-1, OPG-2, OPG-3, OPG-4
models: RNA-Seq murine data that formed the
basis of the original and follow-up analyses. The
non-neoplastic samples are also denoted as FF
(flox/flox control); OPG-1 model is also denoted as
FMC (Gfap-Cre NF1 mutants); the OPG-2 model is
also denoted as F18C (germline F18C NF1
mutants); the OPG-3 is also denoted as FMPC
(Gfap-Cre NF1/PTEN mutants); and the OPG-4
model is also denoted as FMOC (Olig2-Cre NF1
functional states for tumor tissue relative to their normal non-neoplastic counterparts. One
natural outgrowth of this conceptualization is the idea that normal healthy and disease tissues
can be defined in an objective manner using computational approaches. Algorithms have been
used to classify diseased states, to assess risk as a function of specific factors such as gender,
age, and environmental exposures [1–3]; and to identify individualized treatments based on
gene expression profiles [4–6].
In addition to disease state classification, computational modeling can also be employed to
identify ecosystem relationships that exist in the tissue as a whole. One type of model consists
of representing relationships as a network, where the nodes are proteins, transcription factors,
or genes, and the edges between nodes signify communication pathways. Networks highlight
core differences between normal healthy and tumor tissues, and, as such, might serve to iden-
tify unanticipated regulatory pathways germane to the maintenance of the tumor. To investi-
gate potential networks, we leveraged one authenticated murine model of a brain tumor (optic
glioma) that arises in children with the neurofibromatosis type 1 (NF1) cancer predisposition
syndrome [1, 2]. These optic glioma tumors are low-grade (World Health Organization grade
I pilocytic astrocytomas) neoplasms, which develop early in childhood [7]. Since these tumors
are not removed or biopsied in children with NF1, we specifically chose this Nf1 genetically-
engineered mouse low-grade glioma model system, because it recapitulates many of the fea-
tures seen in the human condition and has been successfully employed to evaluate promising
targeted therapies now in clinical trial for children with the tumors [3–6] (http://clinicaltrials.
org; NCT01089101, NCT01158651 and NCT01734512).
Applications of network analysis to the understanding of cancer biology are relatively new,
and can be divided into three methodological types: (1) enrichment of fixed gene sets, (2) de
novo subnetwork construction and clustering and (3) network-based modeling [8]. While
we applied all three methods to characterize murine Nf1 optic gliomas, the network-based
approach (the third type) was the only one with sufficient power to leverage relational network
information to define specific regulator connections.
In this report, we describe one specific type of network analysis based on measures of net-
work complexity [9]. We focused on a standard measure of network complexity predicated on
the idea of centrality, as measured by betweenness. The general idea is that network complexity
analysis reveals sub-networks that are the biggest contributors to genetic complexity. Genetic
complexity equates to a “surplus of genotypic diversity over phenotypic diversity” [10], and is
associated with networks that are more difficult to interpret. Our proof-of-principle study uses
complexity analysis of weighted transcription networks to identify transcription factors that
comprise a regulatory network unique to low-grade brain tumors arising in the optic nerves of
Nf1 mutant mice (optic gliomas). The edges of the transcription network are given weights
based on transcription data, so that the RNA expression data from a normal control group
result in a “normal” network, while data from a group of tumor samples are used to define a
“tumor” network. Having a normal network and a tumor network side-by-side is important
for comparing the two experimental conditions. Using both networks simultaneously, we were
able to identify the Etv5 network as a defining feature of the neoplastic state in mouse and
human low-grade glioma tumors.
Materials and methods
Mice
Nf1flox/flox (N), Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681; GFAP-Cre (OPG-2), Nf1flox/null;
Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice [2, 11–13] were
maintained on a C57Bl/6 background. Mice were housed in standard caging systems, which
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mutants). The samples are publicly available at:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE102345. RNA-Seq Data for 6-month-old
murine non-neoplastic and OPG-1 model: RNA-
Seq murine data on 6-month-old mice. The OPG-1
model is also denoted as FMC (Gfap=Cre NF1
mutants). The samples are publicly available at:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE102345. qPCR Data for 3-month-old
murine OPG-1: In these experiments, we chose 12
genes (Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3,
Spred1, Nlgn3, Dusp6, Lrp4, Rsbn1l, and Socs2)
for qPCR validation in optic nerves from normal
healthy and optic glioma-bearing mice (n=3 mice/
group). Cell-type based expression data from the
brain RNA-Seq database: Data analyzed from the
brain RNA-seq database [18]. The samples are
publicly available at: http://web.stanford.edu/group/
barres_lab/brain_rnaseq.html. Microarray Data for
Pediatric Pilocytic Astrocytoma: The dataset is
available at the NCBI GEO repository, GSE42656
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE42656). We used the samples from 14
pediatric pilocytic astrocytomas and 8 fetal
cerebellum samples. The gene expression samples
were measured using Illumina HumanHT-12 V3.0
expression beadchip. [33] Microarray Data for
Juvenile Pilocytic Astrocytoma: The dataset is
available at the NCBI GEO repository, GSE12907
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE12907). We used the samples from 21
juvenile pilocytic astrocytomas and four normal
cerebellum samples. The gene expression samples
were measured using an Affymetrix Human
Genome U133A array. [34]
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included irradiated commercial mouse chow and acidified water available at all times. Tem-
peratures were kept at 70–72˚F with 50–60% humidity on static racks. Light cycles were set at
5:00am on and 7:00pm off. All cages include pressed cotton squares for environmental enrich-
ment that were changed multiple times per week. Every animal was checked at least once per
day, and mating cages and cages with litters were checked twice per day for appearance, move-
ment and overall health to monitor well-being. Mice were euthanized with 200 mg/kg sodium
pentobarbital via i.p. prior to tissue isolation. All procedures were performed in accordance
with an approved Animal Studies Committee protocol at Washington University with associ-
ated ethics committee approval.
Immunohistochemistry
Optic nerves were microdissected and processed as described previously [14, 15]. Rabbit anti-
Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry.
RNA isolation
Mice were perfused, followed by optic nerves/chiasms microdissection, and preservation in
TRIzol solution. RNA was isolated by phenol/chloroform extraction followed by isopropanol
precipitation. RNA from primary astrocytes was isolated using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s protocol.
Quantitative real-time PCR
qPCR was performed as described previously [16]. The primers used for these experiments are
listed in S1 Table.
Primary astrocyte culture
Wild-type and Nf1-/- primary astrocytes were generated and maintained as previously
described [17–20].
RNA-seq experiments
RNA-sequencing of optic nerves/chiasms isolated from 6-weeks-old mice was performed as
previously described [15].
Regulatory network construction
The glioma network was inferred from the Rembrandt microarray data set (available from
GEO GSE68848 [21]). The Rembrandt data were generated through the Glioma Molecular
Diagnostic Initiative and include 874 glioma specimens. With the Rembrandt data, the net-
work was built using the ARACNe-AP algorithm [22, 23].
The ARACNe-AP algorithm reconstructs gene regulatory networks from large-scale gene
expression data [23]. The steps used in this algorithm are summarized below:
1. The input to the algorithm is a list of transcription facts and gene expression profile data.
2. The gene expression data is pre-processed in order to determine a mutual information
(MI) threshold. Specifically, all pairwise MI scores between gene expression profiles are esti-
mated, and then their significance assessed by comparing them to a null dataset. The signif-
icance level depends on the sample size of the input.
3. The bootstrapping step: selecting a random sample from the input gene expression profiles.
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a. The gene expression profiles are rank-transformed, and then the MI for each Transcrip-
tion Factor/Target pair is calculated.
b. The MI threshold from Step 2 is used to remove any connections that are not statistically
significant.
c. Indirect interactions are removed using the Data Processing Inequality tolerance filter
described in [22].
4. A network is constructed using consensus, by keeping only edges that were detected a sig-
nificant number of times across all bootstrap runs in Step 3. Significance is determined
using a Poisson distribution, keeping only those edges with a p-value less than 0.05.
The ARACNe algorithm, first described in [22], has been successfully used for over a
decade. The Adaptive Paritioning version of the algorithm improves on the original method
by eliminating the use of pre-determined bins of fixed sizes for estimating the mutual informa-
tion. The resulting ARACNe-AP algorithm and its validation are described in detail in [23].
Various networks constructed using the algorithm are available online from bioconductor.org
as the aracne.networks data package. The regulatory network used in this study is provided as
part of the supplementary materials (S2 Table).
Centrality calculations
RNA expression data from optic nerves of Nf1flox/flox (N, normal control group, n = 4) and
Nf1flox/mut; GFAP-Cre (OPG-1, tumor group, n = 11) were generated previously [15] and used
to create separate weighted networks. Note that the network structure is the same for the two
groups, but the weights assigned to the edges differ. Genes that were not expressed in one of
the groups were removed from the network. The network weights are given by the distance
between two nodes (i.e., between two genes). The distances between two genes (j and k) are
calculated as 1 − | ρ(xj, xk)| where ρ(xj, xk) is the minimum of the Pearson and Spearman corre-
lations between the expression levels of gene j and gene k.
The betweenness centrality of gene i is the fraction of shortest paths in the network that go
through gene i. Note that our original choice of transcriptome network built by the ARACNe-
AP algorithm has a consequence that only regulators (and not their targets) have high central-
ity measures. Centrality measures were calculated using the igraph package in R [24].
Differential expression analysis
The differential expression and fold change calculations on the RNA-Seq datasets (including all
of the OPG datasets) were performed using the R package DESeq2 version 1.18.1 [25], including
use of Benjamini-Hochberg adjusted p-values [26] with an adjusted significance level of 0.01.
Published microarray data were analyzed by comparing pilocytic astrocytomas and normal
control samples. The publicly available data were already normalized, and we performed stan-
dard two-sample t-tests on all probes in each dataset. After analysis at the probe level, data were
collated based on the gene to which the probes mapped. Because the analysis was confirmatory
for ETV5 and its network (and not exploratory), we did not adjust for multiple comparisons.
Details of the datasets employed
1. RNA-Seq Data for 3-month-old murine non-neoplastic and OPG-1, OPG-2, OPG-3, OPG-
4 models. RNA-Seq murine data that formed the basis of the original and follow-up analy-
ses. The non-neoplastic samples are also denoted as FF (Nf1flox/flox); OPG-1 model is also
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denoted as FMC (Nf1flox/null; GFAP-Cre); the OPG-2 model is also denoted as F18C
(Nf1flox/R681; GFAP-Cre); the OPG-3 is also denoted as FMPC (Nf1flox/null; Ptenflox/wt;
GFAP-Cre); and the OPG-4 model is denoted as FMOC (Nf1flox/null; Olig2-Cre). The
samples are publicly available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE102345.
2. RNA-Seq data for 6-week-old murine non-neoplastic and Nf1 OPG-1 model0 RNA-Seq
murine data on 6-week-old OPG-1 (FMC) mice. The OPG-1 model is also denoted as
FMC. The samples are publicly available at https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE102345.
3. qPCR data for 3-month-old murine Nf1 OPG-1 model. In these experiments, we chose 12
genes (Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1, Nlgn3, Dusp6, Lrp4, Rsbn1l, and
Socs2) for qPCR validation in optic nerves from normal healthy and optic glioma-bearing
mice (n = 3 mice/group), 8 genes that demonstrated differential expression patterns similar
to the original RNA-seq data (Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1 and Nlgn3,
Fig 1), while 4 demonstrated different patterns or no change (Dusp6, Lrp4, Rsbn1l and
Socs2, data not shown). The p-values were calculated using a t-test (GraphPad, Prism).
4. Cell-type based expression data from the brain RNA-Seq database. Data analyzed from the
brain RNA-seq database [27], Fig 2 compares the expression levels in various cell types. The
samples are publicly available at http://web.stanford.edu/group/barres_lab/brain_rnaseq.
html.
Fig 1. The Etv5 network is differentially expressed in murine Nf1 optic gliomas. Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1 and Nlgn3
RNA expression is increased in optic glioma samples (OPG-1) relative to the normal murine optic nerve (N). n.d., not detected. FC, fold change.
p = 0.0003 (Gldc), p = 0.0258 (Spry4), p<0.0001 (Fabp5), p = 0.0005 (Spry2), p = 0.0045 (Shc3), p = 0.0111 (Spred1), p = 0.0008 (Nlgn3). The
unadjusted p-values were calculated separately using a t-test.
https://doi.org/10.1371/journal.pone.0190001.g001
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5. Microarray data for pediatric pilocytic astrocytomas. The dataset is available at the NCBI
GEO repository, GSE42656 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE42656), which included 14 pediatric pilocytic astrocytomas and 8 fetal cerebellum sam-
ples. The gene expression samples were measured using Illumina HumanHT-12 V3.0
expression beadchip [28]. In addition, GSE12907 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE12907), contained 21 juvenile pilocytic astrocytomas and four nor-
mal cerebellum samples. The gene expression samples were measured using an Affymetrix
Human Genome U133A array [29].
Fig 2. Expression of Etv5 network in the central nervous system. (A) Etv5 RNA expression in astrocytes, neurons, OPCs (oligodendrocyte progenitor
cells), newly formed oligodendrocytes, myelinating oligodendrocytes, microglia and endothelial cells demonstrates preferential enrichment in
astrocytes, OPCs and microglia. Data analyzed from the brain RNA-Seq database [27] (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html).
(B) Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1 and Nlgn3 expression was enriched in astrocytes, OPCs and microglia. Spred1 was the only gene
expressed in microglia.
https://doi.org/10.1371/journal.pone.0190001.g002
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Results
The network complexity analysis in this case study is divided into two steps: (1) discovery of
Etv5 with computational methods and (2) validation of Etv5 with independent experimental
techniques. The edges of the transcription network are given weights based on expression data
such that expression data from a normal control group (N, optic nerves from Nf1flox/flox mice,
which are equivalent to wild-type mice [2]), result in a “normal” network, while data from a
group of optic glioma tumor samples (OPG-1, optic nerves from Nf1flox/null; GFAP-Cre mice,
[2]) comprise a “tumor” network. While the individual bioinformatics steps are not new,
our novel approach illustrates how this practical approach can be implemented to identify
unknown regulatory networks.
First, we use network complexity to identify genes that are central to the tumor network.
Herein, the term central is used in the context of network complexity analysis: a node’s central-
ity measure is determined by the frequency with which it appears in paths between other
nodes in the network, as described below. Next, we identify a single transcription factor, Etv5,
not previously implicated in low-grade glioma, as the gene most differentially central: As
such, Etv5 was the gene most central in the tumor network, and was not central in the normal
network. Finally, we validated the differential expression of Etv5 in several other Nf1 murine
models of optic glioma, as well as in human low-grade glioma (pilocytic astrocytoma, PA)
datasets. This validation was accomplished by comparing expression levels of Etv5 and its tar-
get genes in normal healthy optic nerves and optic gliomas, as well as by determining the cell
type expression profiles of those genes.
Bioinformatic discovery of Etv5
In our analysis, we employed two distinct computational techniques (network and differential
expression analyses) to provide different information about the relationships between the
genes within the networks and across the experimental conditions. The discovery of Etv5 and
its network was only possible using the combination of the different computational techniques
(see Algorithm 1).
Network and complexity analysis
In order to identify genes that might play a role in disease evolution, we sought to determine
what has changed in the intra-cellular network that describes cellular processes. We also
sought to identify genes whose role had significantly changed as the tissue evolved from a
healthy to a diseased state. This study describes how to combine a centrality analysis with dif-
ferential expression to identify potential genes of interest. In order to do this, we required a
network that represented possible interactions between genes. We utilized expression data
from samples in different groups (healthy and diseased, for example) to add weights to an
existing interactome to create a weighted network for each group. This allowed us to identify
“important” subnetworks in each network, and to determine which genes are central to the
important subnetworks in the diseased tissue.
A gene regulatory network (GRN) depicts how some genes encoding regulatory molecules,
such as transcription factors or microRNAs, regulate the expression of other genes [30]. As the
base network for the Etv5 analysis, we used a regulatory network based on biological interactions
between transcription factors and their targets. This network was developed in prior research by
another group, and is described more fully in [23]. The nodes of the network represent regulator
and target genes, and the edges represent protein-DNA interactions. The regulatory network
was derived from transcription (RNA) data, representing a variety of different gliomas, includ-
ing low-grade (benign) and high-grade (malignant) gliomas, to capture pan-glioma regulatory
Identification of ETV5 in a low-grade glioma network
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interactions. Four hundred twenty-seven human glioma gene expression profiles were obtained
from the Rembrandt data repository [21], and these were combined to create a network using
the ARACNe-AP (Algorithm for the Reconstruction of Accurate Cellular Networks). This net-
work was selected as the most appropriate to use, since it is based on transcription data from gli-
omas. We added edge weights to this network using RNA expression data, as described below.
The details of the ARACNe algorithm are provided in [23]: The basic procedure uses mutual
information (MI) to measure similarity across genes and then bootstrapping to measure the
strength and consistency of the similarities. A step-by-step description of the algorithm is pre-
sented in the Materials and Methods section. The regulatory network is available as S2 Table.
Centrality measures are commonly used to identify nodes that could potentially play
important roles in weighted networks [31]. Some frequently used centrality measures are
closeness, betweenness, and entropy; for example West et al. use differential entropy between
tumor and normal tissue to detect relevant genes [32]. The betweenness measure was selected
as the best for distinguishing between normal control and tumor-weighted networks, since its
large range of values led to a clear discrimination between the tumor and control networks.
Fig 3 and S1 Fig show the comparison of using betweenness and closeness to differentiate the
tumor and normal networks. The betweenness metric identifies genes that are substantially
different across the two networks; the closeness metric does not identify any such stand-out
genes. It should be noted that Etv5 was not among the 50 most differentially-expressed genes
Fig 3. Comparison of betweenness measures in the normal and tumor networks. Filled (red) circles indicate genes whose betweenness measure is
at least 1.1 times as large in the tumor network as in the normal network and either a tumor betweenness or normal betweenness value greater than
1e6. These genes are listed in Table 1, and shown in pink in Fig 4.
https://doi.org/10.1371/journal.pone.0190001.g003
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by standard differential expression analysis, and it is unlikely that it would have been identified
as a potential glioma network regulator.
The Betweenness Centrality of gene i (i.e., node i), bi, is the fraction of shortest paths in the






where nj,k is the number of shortest paths connecting genes j and k, and nj,k(i) is the number of
shortest paths that also go through gene i. The length of the path between any two genes is
given by the sum of the distances, or weights, of its edges, where the distances were computed
using the expression data. Because the edge values are based on the expression data, the
betweenness measures will differ between the normal and tumor expression networks. Impor-
tantly, the genes with larger betweenness values in the tumor expression network relative to
the normal expression network were identified.
Using the 3-month-old murine OPG-1 RNA-Seq dataset, 22 genes were identified as having
betweenness values at least 1.1 times as large in the tumor expression network as in the normal
expression network and either a tumor betweenness or normal betweenness value greater than
1e6. These genes are shown as solid, red circles in Fig 3; listed in Table 1; and denoted as “cen-
tral” to the expression network.
Algorithm 1: Identifying Etv5 network
1. A reference network is identified for all transcription factors. In this study we use the regu-
latory network created with the ARACNe-AP algorithm
2. Weights are added to the edges of the reference network using one minus the minimum of
the Pearson or Spearman correlation of RNA-Seq data. Two different weighted networks
are created—one with tumor RNA-Seq data and one with normal RNA-Seq data
3. From each weighted network, the betweenness value for each gene is calculated
4. Genes with betweenness values 1.1 times as big in the tumor network relative to the normal
network and having either a tumor betweenness or a normal betweenness greater than 1e6
are identified. These genes are considered “central” in the tumor network (Table 1).
5. Of the “central” genes, the most differentially expressed gene is identified (Etv5).
6. Genes which represent targets of the Etv5 transcription factor and are differentially
expressed across the two conditions were identified (Table 2).
Identification of ETV5
Once the twenty-three “central” genes were identified, we determined which of them behaved
differently in the two groups with respect to average RNA expression. One gene, Etv5, emerged
as having a large differential effect across the two expression datasets on the 3-month-old
Table 1. “Central genes”: Transcription factors identified as having betweenness values at least 1.1 times as large in the tumor expression network as in the normal
expression network and either a tumor betweenness or normal betweenness value greater than 1e6.
Cebpz Etv5 Spen Zcchc14 Camta1 Chd5 Cers2
Hnrnpab Ilf2 Zcchc17 Zc3h15 Tulp4 Purb Rpl7
Tcf3 Tead1 Cnbp Prdm2 Sarnp Zranb2 Gcsh
Ift74 Myl12B
https://doi.org/10.1371/journal.pone.0190001.t001
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murine OPG-1 samples. Using the original regulatory network, we identified the target genes
for each of the regulators listed in Table 1. Differential expression analysis was employed to
identify which of the central genes and which of their target genes were significantly different
between the tumor (OPG-1) and the normal (N) 3-month-old samples.
Importantly, of the regulator genes that were determined to be “central” according to the
betweenness measure (Table 1), the gene that was mostly clearly differentially expressed was
Etv5 (Table 3). Additionally, Etv5 also had the highest percentage of differentially-expressed
targets of all of the central genes (Table 4). A list of the 31 differentially-expressed Etv5 target
genes is shown in Table 2. The network consisting of the central regulators, along with the dif-
ferentially expressed targets of Etv5 is shown in Fig 4. Henceforth, we call the subnetwork con-
sisting of Etv5 and its differentially expressed targets as “the Etv5 network”.
Experimental validation
To extend the in silico findings, and to validate Etv5 as a differentially-expressed tumor-specific
gene, we performed a series of complementary experiments. These experiments showed that
Table 2. Thirty-one targets of Etv5 are differentially expressed in 3-month-old murine OPG-1 RNA-Seq samples.
GENE p-value Adjusted p-value log2 Fold Change
Spry2 1.13E-08 2.41E-06 0.916
Dnajb4 2.63E-05 1.65E-03 -0.457
Col2a1 1.07E-04 4.43E-03 1.235
Spred1 1.04E-05 7.78E-04 0.800
Dusp6 1.50E-04 5.54E-03 0.637
S1pr1 6.84E-17 9.28E-14 1.358
Ak4 5.38E-05 2.77E-03 0.959
Fabp5 1.39E-09 3.93E-07 1.087
Fabp7 6.22E-05 3.02E-03 0.956
Rsbn1l 2.16E-04 7.15E-03 -0.428
Btbd3 7.12E-09 1.62E-06 0.755
Gap43 1.94E-05 1.27E-03 -0.797
Gja1 3.64E-10 1.26E-07 0.600
Gldc 6.60E-06 5.29E-04 1.161
Kcnip1 3.06E-04 9.09E-03 -0.797
Igfbp6 3.07E-04 9.10E-03 -0.942
Lrp4 5.38E-05 2.77E-03 0.671
Mmp15 2.11E-04 7.07E-03 1.003
Nt5e 1.18E-04 4.76E-03 -0.744
Pcdhgc3 2.12E-06 2.09E-04 0.932
Tppp3 6.01E-05 2.94E-03 -0.912
Shc3 2.71E-04 8.35E-03 0.903
Nlgn3 1.82E-05 1.21E-03 0.705
Spata6 1.62E-04 5.86E-03 -0.552
Elovl2 1.62E-11 9.28E-09 1.908
Spry4 5.77E-05 2.87E-03 1.104
Socs2 1.77E-04 6.28E-03 -0.814
Slc9a3r1 1.41E-06 1.51E-04 0.722
Chst2 2.28E-11 1.26E-08 1.163
Cxcl14 4.88E-17 7.29E-14 1.425
Dock4 2.88E-05 1.73E-03 0.642
https://doi.org/10.1371/journal.pone.0190001.t002
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Etv5 and its targets are differentially expressed in different cell types, at different stages of
tumor growth, and in different organisms, and lend further credence to the notion that Etv5
and its associated target genes comprise a potential regulatory network in neoplastic tissue rel-
ative to their normal healthy, non-neoplastic counterparts.
In addition to RNA-Seq experiments, we also used quantitative real-time PCR (qPCR) to
analyze Etv5 RNA expression in independently-generated non-neoplastic (Nf1flox/flox [2];
abbreviated N for normal) and tumor-bearing (Nf1flox/null GFAP-Cre [2]; “OPG-1”) optic
nerves. For these studies, four nerves and chiasms from each group were removed from
3-month-old mice at a time when optic gliomas in these mice are first detected [33]. Consistent
with the RNA-seq data, Etv5 expression was detected in the tumor-bearing optic nerves, but
not in their non-neoplastic counterparts (Fig 5A). Moreover, Etv5 protein expression was also
observed in optic glioma tissue, but not in normal healthy optic nerves, by immunohistochem-
istry with an Etv5-specific antibody on paraffin-embedded formalin-fixed specimens (Fig 5B).
Collectively, these results validate the tumor-specific expression of Etv5 at both the RNA and
protein levels.
As an additional method to strengthen the specificity of the observed differential Etv5
expression in the neoplastic tissue, we performed RNA-seq analysis on 6-week-old optic
nerves from normal healthy and optic glioma-bearing mice (n = 3 mice/group). At this stage
of glioma development, the tumors are just beginning to form, as evidenced by an increase in
tumor proliferation and glial cell numbers, but without a change in optic nerve volume [33].
Similar to the results obtained from 3-month-old mouse specimens, there was differential Etv5
RNA-Seq expression in 6-week-old optic glioma-bearing mice, which contain a developing,
Table 3. Differential expression of central genes identified using the betweenness measure.
GENE p-value Adjusted p-value log2 Fold Change
Etv5 1.34E-09 3.87E-07 1.4474
Myl12B 6.81E-04 1.61E-02 -0.5850
Zc3h15 4.03E-03 5.12E-02 -0.5603
Camta1 4.22E-03 5.24E-02 -0.4705
Spen 4.61E-03 5.55E-02 0.5714
Tulp4 6.11E-03 6.48E-02 0.4845
Sarnp 7.36E-03 7.24E-02 0.7022
Zcchc17 9.34E-03 8.26E-02 -0.6699
Ift74 9.66E-03 8.43E-02 -0.5475
Tcf3 1.29E-02 9.89E-02 0.4928
Zcchc14 3.82E-02 1.80E-01 0.3660
Rpl7 3.83E-02 1.80E-01 -0.5100
Cnbp 4.16E-02 1.88E-01 -0.3724
Zranb2 6.71E-02 2.47E-01 -0.3515
Tead1 1.40E-01 3.70E-01 0.2794
Ilf2 1.51E-01 3.83E-01 -0.3077
Cebpz 1.60E-01 3.96E-01 -0.3255
Gcsh 3.92E-01 6.38E-01 -0.1581
Cers2 5.36E-01 7.49E-01 -0.0923
Hnrnpab 6.23E-01 8.06E-01 0.0784
Purb 6.80E-01 8.43E-01 0.0573
Prdm2 8.75E-01 9.45E-01 0.0207
Chd5 8.98E-01 9.57E-01 -0.0334
https://doi.org/10.1371/journal.pone.0190001.t003
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but not mature, tumor [33] (S2 Fig). These observations suggest that differential expression of
Etv5 defines a ground state of neoplasia that exists at a time when it is not yet possible to clearly
classify the mouse optic nerve as a tumor.
Numerous prior studies from our laboratory have employed differential RNA expression
methods to identify genes unique to murine Nf1 optic glioma. These include an analysis of
neoplastic and non-neoplastic cell types; however, none of these previous studies identified
Etv5 as a differentially-expressed gene [16, 34]. In this respect, previous studies including gene
expression profiles for isolated cells in optic glioma did not find that Etv5 was differentially
regulated in any specific single cell type (e.g., astrocytes, microglia). These particular findings
were confirmed by the analysis of Nf1-deficient neoplastic cells (astrocytes) by qPCR (S3 Fig)
and tumor-associated microglia (non-neoplastic cells [16]) using isolated cells and data previ-
ously acquired. Taken together, these observations argue that differential Etv5 expression
reflects a “whole tumor” property, rather than representing the individual contributions from
any single cell type within the tumor.
Next, we sought to determine whether the target genes of Etv5, which were differentially
expressed in the tumor, are similarly differentially expressed in tumor-bearing optic nerves rel-
ative to normal healthy non-neoplastic optic nerve. In these experiments, we chose 12 genes
(Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1, Nlgn3, Dusp6, Lrp4, Rsbn1l, and Socs2) for
independent validation by qPCR (Fig 1). Of the 12 genes chosen, 67% demonstrated differen-
tial expression patterns similar to the original RNA-seq data (Gldc, Spry4, Fabp5, Pcdhgc3,
Table 4. Percent of target genes (from the regulatory network) that are differentially expressed by each of the cen-
tral genes identified using the betweenness measure.
GENE #significant Total targets % significant
Etv5 31 449 0.0690
Cers2 32 496 0.0645
Sarnp 15 255 0.0588
Zcchc14 16 361 0.0433
Tcf3 28 640 0.0437
Tead1 19 443 0.0429
Zc3h15 27 652 0.0414
Tulp4 17 412 0.0413
Rpl7 10 247 0.0405
Purb 27 678 0.0398
All 529 14926 0.0354
Hnrnpab 19 543 0.0350
Cnbp 15 458 0.0328
Camta1 35 1093 0.0320
Chd5 27 852 0.0317
Zcchc17 8 257 0.0311
Prdm2 20 652 0.0307
Spen 12 392 0.0306
Cebpz 10 379 0.0264
Ilf2 13 555 0.0234
Zranb2 11 486 0.0226
Gcsh 0 0 0
Ift74 0 0 0
Myl12B 0 0 0
https://doi.org/10.1371/journal.pone.0190001.t004
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Spry2, Shc3, Spred1 and Nlgn3), while four demonstrated different patterns or no change
(Dusp6, Lrp4, Rsbn1l and Socs2).
Because the expression of Etv5 targets in the tumor may reflect the expression of these
genes in different cell types, we queried an established brain cell type-specific transcriptome
database [27]. We focused on Etv5 and those targets that were significantly differentially
expressed (Gldc, Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1 and Nlgn3). Using this brain
RNA-Seq database [27], we found enrichment of Etv5 expression in astrocytes, oligodendro-
cyte progenitor cells (OPC) and microglia relative to endothelial cells, neurons, and more dif-
ferentiated oligodendrocytes (Fig 2A). These findings are consistent with biological studies
demonstrating that astrocytes [2], o-GSCs (optic glioma stem cells) [17], and microglia [6, 16]
are all critical mediators of glioma formation and growth. Interestingly, seven of the eight Etv5
Fig 4. The Etv5 network. The subnetwork is comprised of Etv5 (in lavender in the center), and its differentially-expressed targets
(shown in yellow). The remaining central genes, identified by their high betweenness measures relative to the normal network, are
shown on the periphery in pink.
https://doi.org/10.1371/journal.pone.0190001.g004
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target genes were expressed predominantly in o-GSCs and astrocytes, whereas Spred1 was
expressed in all three cell types (Fig 2B). These observations additionally support the idea that
the network formed by Etv5 and its targets reflects a global change in the tumor ecosystem,
rather than differential gene expression by only one cell type in the tumor.
To demonstrate that differential Etv5 expression is a hallmark of murine Nf1 optic glioma,
we leveraged prior data from our laboratory in which multiple distinct genetically-engineered
mouse models of optic glioma were generated. Each of these models differs in important
respects, including the germline Nf1 gene mutation (OPG-2; c.2041C>T; p.R681X as seen in
several patients with NF1-OPG [12]), the presence of additional genetic mutations (OPG-3;
additionally harboring heterozygous Pten loss [11]), and the tumor cell of origin (OPG-4;
Nf1flox/mut; Olig2-Cre in which tumors arise from Olig2+ cells). While the four optic glioma
models are histologically similar to each other, they represent molecularly-distinct tumors, as
assessed by RNA-seq analysis [15]. In each of the murine Nf1 OPG models, we observed
increased Etv5 RNA expression (Table 5). Moreover, in at least three out of the four optic
Fig 5. Etv5 differential expression is confirmed using qPCR on independently-generated murine Nf1 optic gliomas. (A) Etv5 expression was
detected in in one representative murine Nf1 optic glioma model (OPG-1) but was not detected (n.d.) in the normal murine optic nerve (N) by
qPCR. (B) Immunohistochemistry using Etv5-specific antibodies demonstrates Etv5 protein expression in the optic glioma (OPG-1, shown in
brown), but not in the normal optic nerve (N). Nuclei are stained with hematoxylin (shown in blue). Scale bar, 20μm.
https://doi.org/10.1371/journal.pone.0190001.g005
Table 5. Summary of differential Etv5 expression in additional murine Nf1 optic glioma models.
Gene OPG-1 OPG-2 OPG-3 OPG-4
Etv5 2.74 3.54 2.40 2.07
Gldc 2.25 2.85 1.76 1.50
Spry4 2.16 3.04 1.81 1.81
Fabp5 2.13 n.s. 1.69 2.15
Pcdhgc3 1.91 1.91 1.65 1.44
Spry2 1.89 1.62 1.37 n.s.
Shc3 1.88 2.45 1.74 1.84
Spred1 1.74 1.96 n.s. 1.71
Nlgn3 1.63 1.74 1.61 1.62
Values connote fold changes in optic glioma (OPG) RNA expression relative to non-neoplastic (Nf1flox/flox) optic
nerve (n.s., not significant for DESeq2 test, p-values adjusted using Benjamini-Hochberg).
https://doi.org/10.1371/journal.pone.0190001.t005
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glioma models, there is increased expression of the eight validated Etv5 target genes (Gldc,
Spry4, Fabp5, Pcdhgc3, Spry2, Shc3, Spred1 and Nlgn3) (Table 5). These findings further
strengthen the conclusion that differential Etv5 expression is a hallmark of the neoplastic state,
as it is shared amongst multiple distinct murine Nf1 optic glioma models.
Finally, to determine whether differential ETV5 expression is also a feature of human pedi-
atric low-grade gliomas (pilocytic astrocytoma; PA), we leveraged the only two human RNA
microarray datasets that contained reference non-neoplastic tissue for comparison (GSE42656
and GSE12907). We chose these datasets for two major reasons: First, there are no currently-
available datasets with RNA expression data on NF1-associated optic glioma and normal optic
nerve, since these tumors are rarely biopsied as part of routine medical care. Second, while the
genetic etiology of sporadic and NF1-associated PA are distinct, they both result in activation
of the same growth control pathways [3, 35–39] and are histologically similar [40].
In both the pediatric and the juvenile pilocytic astrocytoma datasets, ETV5was differen-
tially expressed in the tumor groups relative to the non-neoplastic samples (Fig 6), similar to
that observed in the mouse low-grade gliomas. Moreover, using the thirty-one Etv5 target
genes that were differentially expressed in the murine tumors (Table 2), a large fraction of the
probes for those targets were also differentially expressed (unadjusted p-values) in the two
human datasets (56.1% in the pediatric pilocytic astrocytoma dataset and 40.8% of the probes
in the juvenile pilocytic astrocytoma dataset; Fig 7).
Fig 6. Differential expression of ETV5 in human pilocytic astrocytomas. ETV5 is differentially expressed in the
tumor groups from both datasets. Using the pediatric pilocytic astrocytoma data, both of the two Illumina probes for
ETV5 are significantly differentially expressed (p < 0.0001 for both probes). Using the juvenile pilocytic astrocytoma
data, all three of the Affymetrix probes are significantly differentially expressed (p = 0.001, p = 0.00005, p = 0.00003 for
the three probes). Vertical axis is on a log2-scale.
https://doi.org/10.1371/journal.pone.0190001.g006
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Discussion
Leveraging the betweenness network analysis and RNA-sequencing of murine optic glioma
tissues, we discovered Etv5 and Etv5-associated genes as a differentially-regulated transcrip-
tional network in low-grade brain tumors relative to non-neoplastic brain tissue. We further
validated the differential expression of Etv5 and its target genes in several other murine mod-
els of Nf1 optic glioma, as well as in human pilocytic astrocytomas. This type of network
analysis is extremely useful in identifying potential network regulators unique to the neoplas-
tic state, since multiple differentially-expressed genes were identified in tumor versus normal
healthy tissue. In addition, the deployment of multiple computational and statistical analysis
strategies, as well as biological validation across species and time further strengthen the idea
that Etv5 may be a central control element in establishing and/or maintaining low-grade gli-
omas. Moreover, the identification of Etv5 and its network as a tissue-level signature is
Fig 7. Differential expression of ETV5 network genes in human pilocytic astrocytoma. Histograms of (unadjusted) p-values for differential
expression of ETV5 target genes in two human data sets; vertical lines are drawn at p = 0.05. In the GSE42656 dataset, 56.1% of all probes and 64.5% of
the target genes are significantly differentially expressed (top panel). In the GSE12907 dataset, 40.8% of all probes and 38.7% of the target genes were
significantly differentially expressed (middle panel). In the 6-week-old murine OPG-1 data set, 48.3% of the target genes were significantly differentially
expressed (lower panel).
https://doi.org/10.1371/journal.pone.0190001.g007
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supported by the lack of differential Etv5 expression in isolated Nf1-deficient astrocytes or
Nf1-mutant microglia, which are the major neoplastic and non-neoplastic cells in the optic
glioma ecosystem.
ETV5 is a transcription factor that belongs to the conserved E26 transformation-specific
family of transcription factors. Relevant to our study, ETV5 levels are elevated in many tumors,
including glioma [41–43]. As such, ETV5 has been hypothesized to function downstream of
RAS [44], which is consistent with the major role of the Nf1 protein (neurofibromin) as a nega-
tive regulator of RAS in the brain [3, 19]. In addition, ETV5 function is required to sustain
Nf1-deficient high-grade glioma growth [43], but had not been previously implicated in low-
grade gliomas. Since ETV5 expression is not a hallmark of any particular neoplastic cell type in
the low-grade gliomas, it is most likely that the network established reflects aberrant RAS acti-
vation in numerous cell types in the tumor. Future mechanistic studies will be required to
address the relationships between NF1/RAS/MEK/ERK pathway function, ETV5 network reg-
ulation, and NF1-associated low-grade glioma formation or maintenance.
Taken together, we present a proof-of-concept study that establishes betweenness network
analysis as a valuable tool for identifying central genes unique to the tumor ecosystem. While
this approach nicely illustrates the value of computational and bioinformatic approaches for
characterizing the neoplastic state relative to its non-neoplastic counterpart, further investiga-
tion is required to understand the mechanistic role of Etv5 in glioma formation and mainte-
nance. Based on these findings, we recommend the use of network analysis for similar
expression studies designed to differentiate various tumor states.
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